ANTIBODIES
Contributor Information
- Name Lindy Durrant
- Institute University of Nottingham
Tool Details
- Tool name: Anti-Lewis Y [69/229]
- Clone: 69/229
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC
- Description: MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.
- Immunogen: Colonic Adenoma membranes
- Isotype: IgG3 kappa
- Research area: Cancer; Genetics
- Myeloma used: P3/NS1/1-Ag4.1
- For Research Use Only
Target Details
- Target: Lewis Y
- Target background: MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are Fn glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.
Application Details
- Application: FACS ; IHC
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15Ă°C to -25Ă°C
- Shipping conditions: Shipping at 4Ă°C
Documentation
Related Tools
References
- • Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.
- • Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.
.svg)
Unit size: 
.svg)
.svg)
